Use of recombinant factor VIIA plus continuous infusion of recombinant factor VIII in the hemostasis of type 3 von Willebrand disease with anaphylactic anti-VWF inhibitor

被引：0

作者：

Suzuki, N. ^{[1
]}

Sanda, N. ^{[2
]}

Matsushita, T. ^{[3
]}

Kojima, T. ^{[4
]}

Yamamoto, K. ^{[3
]}

Katsumi, A. ^{[5
]}

Hirashima, K. ^{[1
]}

Kajiura, Y. ^{[2
]}

Takatsu, M. ^{[2
]}

Naoe, T. ^{[1
]}

机构：

[1] Nagoya Univ Hosp, Nagoya, Aichi, Japan

[2] Nagoya Univ Hosp, Dept Clin Lab, Nagoya, Aichi, Japan

[3] Nagoya Univ Hosp, Dept Transfus Med, Nagoya, Aichi, Japan

[4] Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Nagoya, Aichi 4648601, Japan

[5] Natl Ctr Geriatr & Gerontol, Dept Haematol, Tokyo, Japan

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-WE-459

引用

下载

页码：665 / 665

页数：1

共 50 条

[21] Recombinant von Willebrand factor (vonicog alfa) in von Willebrand disease: a guide to its use
Lyseng-Williamson K.A.
Drugs & Therapy Perspectives, 2016, 32 (11) : 456 - 462
[22] Factor-VIII-inhibitor-bypassing-fraction/Recombinant-factor-VIIa/TicagrelorAcquired hemophilia A with anti factor-VIII and lack of efficacy
Reactions Weekly, 2024, 2004 (1) : 209 - 209
[23] Treatment with continuous infusion of a factor VIII von Willebrand factor concentrate (Haemate P(R)) for surgery in patients with von Willebrand disease
Schulman, S
Varon, D
Martinowitz, U
Gitel, S
Inbal, A
BLOOD, 1995, 86 (10) : 754 - 754
[24] Slovakian experience with continuous infusion of factor VIII for surgery in hemophilia A and von Willebrand disease
Batorova, A
Filova, A
Pappova, K
Martinowitz, U
THROMBOSIS AND HAEMOSTASIS, 1997, : PS227 - PS227
[25] Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors
Santagostino, E
Morfini, M
Rocino, A
Baudo, F
Scaraggi, FA
Gringeri, A
THROMBOSIS AND HAEMOSTASIS, 2001, 86 (04) : 954 - 958
[26] An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease
Hancock, John M.
Escobar, Miguel A.
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (03) : 157 - 161
[27] Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity - a rebuttal
Makris, M
Van Veen, JJ
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (04) : 818 - 819
[28] Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2
Menache, D
HAEMOPHILIA, 1998, 4 : 44 - 47
[29] PHARMACOKINETICS (PK) OF VON WILLEBRAND FACTOR (VWF) IN PATIENTS WITH VON WILLEBRAND DISEASE (VWD) AFTER TREATMENT WITH RECOMBINANT VWF OR PLASMA-DERIVED VWF CONCENTRATE.
Wang, Y.
Marier, J.
Vasilinin, G.
Berthoz, F. Truong
Azen, G.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S36 - S37
[30] PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2
van Vliet, Huub H. D. M.
Kappers-Klunne, Mies C.
Leebeek, Frank W. G.
Michiels, Jan J.
THROMBOSIS AND HAEMOSTASIS, 2008, 100 (03) : 462 - 468

← 1 2 3 4 5 →